GS $BMY TYK2i commentary: | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  599 of 750  at  6/27/2019 7:59:57 AM  by

zippypie

The following message was updated on 6/27/2019 8:00:33 AM.

GS $BMY TYK2i commentary:

  
 GS $BMY TYK2i commentary: "BMY will continue to develop their TYK2 asset for psoriasis (Ph3 data mid-2020, followed by mid-2021 launch) which we believe could be BMY’s anchor drug in immunology. We expect 2025 sales of $1.75B, to which we ascribe a 70% probability of success.
 


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 332
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board


About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...